NLRP3 and neoplasm: The third study found that IL-6 was upregulated in oral SCC tissues with a high expression level closely related to advanced tumour size, stage, and poorer survival, while IL-6 could stimulate proliferation and NLRP3 inflammasome activation through the JAK2/STAT3/Sox4 pathway in oral SCC cells, implying that the NLRP3 inflammasome is a therapeutic target in oral SCC (14).